EHS
EHS

Janssen funds cancer study using Vital Connect, physIQ tech

Vital Connect and physIQ are teaming up with the Haga Teaching Hospital in the Netherlands to conduct a study on how wearable biosensors and artificial intelligence can augment care for cancer patients undergoing treatment. Specifically, the study — which is funded by Johnson & Johnson subsidiary Janssen Pharmaceuticals — is looking to see how the technology can detect adverse events in cancer treatment early on. 
EHS
Back to top button